News

VivaVision Biotech Welcomes Leading Ophthalmology Expert

VivaVision Biotech Welcomes Leading Ophthalmology Expert

VivaVision Biotech Strengthens Advisory Board with Expert

Recently, VivaVision Biotech Co., Ltd. (VivaVision) proudly announced the addition of Dr. Quan Dong Nguyen, a globally recognized figure in the field of ophthalmology, to its Scientific Advisory Board. This strategic appointment marks a significant step forward for the company as it furthers its commitment to innovative eye care solutions.

Meet Dr. Quan Dong Nguyen

Dr. Quan Dong Nguyen is currently affiliated with the Byers Eye Institute at Stanford University, where he serves as a professor of ophthalmology and has further appointments in medicine and pediatrics. His research primarily revolves around clinical trials for macular edema, neovascular age-related macular degeneration (AMD), and various ocular inflammatory diseases. Having pioneered evaluations of drugs like aflibercept and ranibizumab, Dr. Nguyen's contributions are foundational in establishing effective treatment protocols for retinal problems.

Impact on VivaVision's Projects

Dr. Nguyen's expertise is expected to significantly enhance VivaVision's research and development initiatives. He expressed enthusiasm about joining the team and highlighted the potential of VivaVision's dual JAK1/TYK2 inhibitors, VVN461 and VVN481, developed for treating ocular inflammatory conditions. These innovative therapies aim to provide patients with safer alternatives to current corticosteroid treatments.

Comments from Leadership

Wang Shen, the Founder and CEO of VivaVision Biotech, expressed honor at having Dr. Nguyen join the advisory board. He emphasized that Dr. Nguyen’s extensive knowledge in managing conditions such as diabetic macular edema and inflammatory diseases will be invaluable as VivaVision continues to expand its research endeavors.

About VivaVision

Established in 2016, VivaVision Biotech focuses on pioneering clinical therapies for ocular diseases. With a commitment to addressing unmet medical needs, the company is advancing leading-edge treatments, including:

Innovative Pipeline Developments

1. VVN461: A dual JAK1/TYK2 immunomodulator designed to manage post-operative inflammation and non-infectious anterior uveitis.

2. VVN001: An investigational remedy for dry eye disease.

3. VVN1901: Targeted treatment for neurotrophic keratitis.

4. VVN481: A non-steroidal treatment for posterior uveitis and related inflammatory conditions.

In addition, VivaVision is dedicated to discovering groundbreaking therapies that tackle both anterior and posterior ocular diseases, effectively addressing the challenges faced by patients worldwide.

Frequently Asked Questions

What is the significance of Dr. Quan Dong Nguyen's appointment?

Dr. Nguyen's experience in clinical trials and ocular diseases strengthens VivaVision's advisory board, enhancing its research capabilities.

What are VVN461 and VVN481?

These are dual JAK1/TYK2 inhibitors aimed at treating ocular inflammatory diseases and offer new options for patients.

When was VivaVision Biotech founded?

VivaVision Biotech was founded in 2016 with a focus on developing innovative therapies for eye diseases.

What conditions does VivaVision's pipeline aim to treat?

VivaVision's pipeline focuses on various ocular diseases, including dry eye disease, inflammation, and retinal disorders.

How does VivaVision approach research and development?

The company emphasizes innovative strategies to address unmet patient needs in ocular health through advanced therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Promising Interim Findings from Medicus Pharma's BCC Study

Updated Category News Views 164

Positive Interim Analysis from Medicus Pharma Ltd Medicus Pharma Ltd. (NASDAQ: MDCX) has recently shared exciting interim results from its SKNJCT-003 Phase 2 clinical study, which focuses on a non-invasive approach to treat basal cell carcinoma (BCC) of the skin. This news marks a significant milestone as the company aims to revolutionize the treatment options available...

Continue Reading
DroneShield's Immediate Response Kit Wins Platinum Award for Innovation

Updated Category News Views 161

DroneShield's Immediate Response Kit Gains Recognition for Innovation DroneShield has recently been awarded the prestigious Platinum Award for Innovation by Military and Aerospace Electronics, showcasing its Immediate Response Kit (IRK) as a cornerstone in drone detection and defeat technology. This award is a testament to the exceptional capabilities of the IRK, which...

Continue Reading
Jefferies Holds ABB Rating; Analysts Assess Mixed Results

Updated Category News Views 65

Jefferies Maintains Hold Rating on ABB Stock Jefferies recently continued its Hold rating for ABB Ltd (NYSE: ABB) and set a price target of CHF50.00, following the company's third-quarter performance report. The report showcased a mixed array of results, with certain metrics outperforming expectations while others showed disappointing trends. During the third quarter, ABB...

Continue Reading
Surgical Clips Market Projected to Reach $1.8 Billion Soon

Updated Category News Views 211

Overview of the Surgical Clips Market Recent analysis of the surgical clips market reveals an impressive valuation of USD 655.9 million in 2023, with projections indicating a potential growth to USD 1.8 billion by 2032. This remarkable increase is attributed to a compound annual growth rate (CAGR) of 11.9% from 2024. Understanding Surgical Clips and Their Importance...

Continue Reading
Public Disclosure of Opening Position by Keywords Studios Plc

Updated Category News Views 74

Public Opening Position Disclosure for Keywords Studios Plc This document provides important information about a public opening position disclosure related to Keywords Studios Plc. It includes details about individuals or entities holding 1% or more of relevant securities. This disclosure is made in accordance with Rule 8.3 of the Takeover Code, which ensures that all...

Continue Reading